Previous 10 | Next 10 |
In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...
EATONTOWN, NJ / ACCESSWIRE / May 6, 2021 / American CryoStem Corporation (OTC PINK:CRYO) a clinical-stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and therapies announced today, that it has signed a Letter of Intent (LOI) with Advanced Regenerat...
EATONTOWN, NJ / ACCESSWIRE / March 11, 2021 / American CryoStem Corporation (OTC: CRYO) a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has begun processing patient's adipose tissue and culturing me...
EATONTOWN, NJ / ACCESSWIRE / February 25, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies, announced today that it has entered into an Agreement with BioTherapeutic Lab...
EATONTOWN, NJ / ACCESSWIRE / January 6, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a clinical stage biotechnology Company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has entered into a Cooperative Research and Development ...
EATONTOWN, NJ / ACCESSWIRE / December 1, 2020 / American CryoStem Corporation (OTC PINK:CRYO) a clinical-stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has commenced recruiting subjects for its IND Phase I Cl...
The FDA has signed off American CryoStem' ([[CRYO]] +15.4%) Phase 1 study to develop ATCell, an expanded autologous adipose-derived mesenchymal stem cell therapy for the treatment of Post-Concussion Syndrome ((PCS)).CRYO will initiate 20-subject Phase 2 study in the next quarte...
EATONTOWN, NJ / ACCESSWIRE / September 23, 2020 / American CryoStem Corporation (OTC PINK: CRYO ) is a clinical stage biotechnology company, global licensor, and a pioneer in autologous cellular therapy processing. The Company has developed proprietary products and services to advance its en...
EATONTOWN, NJ / ACCESSWIRE / August 4, 2020 / American CryoStem Corporation (OTC PINK: CRYO ) (the "Company"), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine indust...
American CryoStem Corporation ( OTCPK:CRYO ) announces conversion of $168K debt into equity , in order to preserve cash available to fund ongoing operations. More news on: American CryoStem Corporation, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
American Cryostem Corp Company Name:
CRYO Stock Symbol:
OTCMKTS Market:
American Cryostem Corp Website:
Eatontown, New Jersey--(Newsfile Corp. - January 6, 2023) - American CryoStem Corporation (OTC Pink: CRYO), a clinical-stage therapeutics company with a proprietary end-to-end core biotechnology platform of tissue-based cellular technologies that powers its clinical pipeline, announced today that...
Eatontown, New Jersey--(Newsfile Corp. - December 22, 2022) - American CryoStem Corporation (OTC Pink: CRYO), a clinical-stage therapeutics company with a proprietary end-to-end core biotechnology platform of tissue-based cellular technologies powering its clinical pipeline, announced today tha...
EATONTOWN, NJ / ACCESSWIRE / March 4, 2022 / American CryoStem Corporation (OTC PINK:CRYO) a clinical stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and cellular therapies, announced today that it has reached the midway point of its ATCellȒ...